Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 11, 2011, Pages 400-407

  Za̧bczyk, Michał ^a   Majewski, Jacek ^a   Lelakowski, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Atrial fibrillation; Clot lysis time; Fibrinolysis; Stroke; Thromboembolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; BODY MASS; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT ATRIUM; HEART SIZE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PROTEIN BLOOD LEVEL; STROKE; THROMBOEMBOLISM;

EID: 83055168976     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1101     Document Type: Article

References (34)

1. Roldán V, Marín F, Blann AD, et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J. 2003; 24: 1373-1380. (Pubitemid 36917709)
2. Sadanaga T, Kohsaka S, Ogawa S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology. 2010; 117: 31-36.
3. Roldán V, Marín F, Marco P, et al. Hypofibrinolysis in atrial fibrillation. Am Heart J. 1998; 136: 956-960. (Pubitemid 29080851)
4. Hatzinikolaou-Kotsakou E, Kartasis Z, Tziakas D, et al. Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations? J Thromb Thrombolysis. 2003; 16: 155-161. (Pubitemid 39137440)
5. Feinberg WM, Macy E, Cornell ES, et al. Plasmin-alpha2-antiplasmin complex in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Thromb Haemost. 1999; 82: 100-103. (Pubitemid 29368780)
6. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011; 27: 74-90.
7. Hart RG. What's new in stroke? Thetop 10 studies of 2006-2008. Part II. Pol Arch Med Wewn. 2008; 118: 747-755.
8. Freestone B, Lip GY, Chong AY, et al. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost. 2005; 94: 702-706. (Pubitemid 41489227)
9. Califano F, Giovanniello T, Pantone P, et al. Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci. 2000; 4: 59-66. (Pubitemid 32782748)
10. Adams TE, Huntington JA. Thrombin-cofactor interactions: structural insights into regulatory mechanisms. Arterioscler Thromb Vasc Biol. 2006; 26: 1738-1745. (Pubitemid 44305326)
11. Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. Thromb Haemost. 2007; 5: 102-115. (Pubitemid 46958823)
12. Meltzer ME, Doggen CJ, de Groot PG, et al. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood. 2010; 116: 529-536.
13. Jankun J, Skrzypczak-Jankun E. Yin and yang of the plasminogen activator inhibitor. Pol Arch Med Wewn. 2009; 119: 410-417.
14. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000; 95: 2855-2859. (Pubitemid 30235895)
15. Montaner J, Ribo M, Monasterio J, et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003; 34: 1038-1040. (Pubitemid 36402986)
16. Małyszko J, Tymcio J. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. Pol Arch Med Wewn. 2008; 118: 36-41. (Pubitemid 351316526)
17. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood. 2010; 116: 113-121.
18. Undas A, Zawilska K, Cieśla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood. 2009; 114: 4272-4278.
19. Undas A, Nowakowski T, Cieśla-Dul M, et al. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis. 2011; 215: 481-486.
20. Undas A, Szułdrzynski K, Stȩpień E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008; 196: 551-557.
21. Undas A, Podolec P, Zawilska K, et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke. 2009; 40: 1499-1501.
22. Meltzer ME, Doggen CJ, de Groot PG, et al. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol. 2009; 145: 121-127.
23. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342: d124.
24. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001; 121: 131-139. (Pubitemid 32591523)
25. Wolberg AS, Monroe DM, Roberts HR, et al. Elevated prothrombin results in clots with analtered fiber structure: a possible mechanism of the increased thrombotic risk. Blood. 2003; 101: 3008-3013. (Pubitemid 36857988)
26. Blombäck M, He S, Bark N, et al. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol. 2001; 152: 758-765.
27. Undas A, Stȩpień E, Tracz W, et al. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost. 2006; 4: 973-975.
28. Undas A, Plicner D, Stepień E, et al. Altered fibrin clot structure in patients with advanced coronary artery disease: arole of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost. 2007; 5: 1988-1990. (Pubitemid 47288965)
29. Undas A, Celinska-Löwenhoff M, Löwenhoff T, et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006; 4: 1029-1036.
30. Undas A, Topór-Ma̧dry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn. 2009; 119: 354-359.
31. Butenas S, Undas A, Gissel MT, et al. Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost. 2008; 99: 142-149.
32. Wrigley BJ, Tapp LD, Shantsila E, et al. Antithrombotic therapy in anticoagulated patients with atrial fibrillation presenting with acute coronary syndromes and/or undergoing percutaneous coronary intervention/stenting. Pol Arch Med Wewn. 2010; 120: 290-293.
33. Rooth E, Wallen H, Antovic A, et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis. 2007; 18: 365-370. (Pubitemid 46699415)
34. Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998; 273: 27 176-27 181.